Disruption, Diversity, and Global Biobanking

Biospecimens, biobanking and global cancer research collaborations

The disparities in prostate cancer incidence and mortality continue to be a global public health problem. Efforts to address the prostate cancer disparity in black men have been met with a number of challenges, specifically in the accessibility to biospecimens in the context of global prostate cancer collaborations. During the International Educational Workshop at the Science of Global Prostate...

Biobanking 3.0: evidence based and customer focused biobanking.

Biobanking is a new and very dynamic field. To achieve long term financial sustainability of biobank infrastructures we propose that a new focus is needed on activities, products and services provided by the biobank that relate to the external stakeholder: biobanking 3.0. Earlier stages of biobanking are biobanking 1.0 (primary focus on the number of biospecimens and data) and biobanking 2.0 (p...

A Robust Competitive Global Supply Chain Network Design under Disruption: The Case of Medical Device Industry

In this study, an optimization model is proposed to design a Global Supply Chain (GSC) for a medical device manufacturer under disruption in the presence of pre-existing competitors and price inelasticity of demand. Therefore, static competition between the distributors’ facilities to more efficiently gain a further share in market of Economic Cooperation Organization trade agreement (ECOTA) is...

Biopreservation & biobanking

Global Phage Diversity

Ten new mycobacteriophage genomes presented by show that most phage diversity remains uncharacterized. Extrapolation suggests that less than 0.0002% of the global phage metagenome has been sampled. The new genomes also contain a number of potential virulence factors that may be important in pathogenesis.